Progress toward personalized management of stage II/III triple negative breast cancer

Cancer Treatment Reviews · Published 2025-01-01 · Journal article · DOI 10.1016/j.ctrv.2026.103143

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ctrv.2026.103143

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2025

Related articles

• ITPKB suppresses ER calcium release to promote CXCL9 expression and enhance immunotherapy sensitivity in triple-negative breast cancer · Drug Resistance Updates · 2026 · Cites or is cited by this article
• Targeting key epigenetic regulators in solid tumors: focus on EZH2, PRMT5, and BET inhibitors · Cancer Treatment Reviews · 2026 · Same journal
• Glioblastoma and resistance to radiotherapy: role of cancer stem cells subpopulations, hypoxia and therapeutic strategies · Cancer Treatment Reviews · 2026 · Same journal
• Pharmacological prevention of second primary cancers: From chemoprevention to precision cancer interception · Cancer Treatment Reviews · 2026 · Same journal
• Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation · Cancer Treatment Reviews · 2026 · Same journal
• Multigene assays in early breast cancer: Current evidence, limits and future directions · Cancer Treatment Reviews · 2026 · Same journal
• Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection · Cancer Treatment Reviews · 2026 · Same journal
• Cellular senescence: A novel mechanism of therapeutic resistance in prostate cancer · Cancer Treatment Reviews · 2025 · Same journal
• Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study · Cancer Treatment Reviews · 2026 · Same journal
• KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians · Cancer Treatment Reviews · 2026 · Same journal